Sign inJoin waitlistJoin the waitlist

Coleen Cunningham

Chair — Pediatrics · University of California

Credentials: · ·

History

University of California
Present
CHOC/UC Irvine School of Medicine Division · University of California
Present
University of California
Present

Infectious Disease
1988–1990
Internal Medicine
SUNY Upstate Medical University
1985–1988
State University of New York Upstate Medical University
1981–1985

Research

Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity
The Journal of Experimental Medicine · 2007 · 302 citations
Respiratory syncytial virus and influenza A infections in the hospitalized elderly
The Journal of Infectious Diseases · 1995 · 298 citations
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial
JAMA · 2002 · 269 citations

Elizabeth McFarland
26 papers
Matthew Kelly
24 papers · 6 as a fellow
Andrew Steenhoff
19 papers
Dorothy Dow
17 papers · 4 as a fellow
Kristen Feemster
15 papers
LM
Lynne Mofenson
15 papers
Samir Shah
15 papers
Tonya Obita
15 papers
Patricia Flynn
12 papers
Sallie Permar
12 papers
Stephen Spector
12 papers
Leonard Weiner
11 papers

Grants

Institutional Training Grant in Pediatric Infectious Disease
National Institute of Child Health and Human Development · T32
Contact PI · $1M · Duke University
2011–2016
Pediatric AIDS Clinical Trials Unit
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $2.1M · Duke University
1989–2007

Clinical trials

Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
Study chair · Recruiting · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2026–2028
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
Study chair · Terminated · Phase 1, Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
2019–2024
Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants
Study chair · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2015–2021
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Study chair · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2010–2012